Clinical trials: Clarithromycin
HELICOBACTER PYLORI INFECTIONS, Gastrointestinal Disease
Evaluation of IgY Antibody Efficacy in Egg Yolk Against Helicobacter Pylori in Bacterial Elimination and Clinical Symptoms Improvement of Gastrointestinal Patients
1. Investigating its effectiveness in removing bacteria in invivo conditions 2. Investigating the effectiveness in improving the clinical symptoms of patients
- Trial name
- Hp IgY (NCT06973889)
- Testing
- Helicobacter pylori eradication therapy
- Where
- 2 sites in Iran
- Volunteers
- 60 people
- Sponsor
- Mashhad University of Medical Sciences
Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.
The purpose of this study is to assess efficacy of 10-day antimicrobial susceptibility test guided triple therapy for the first-line treatment of Helicobacter pylori infection, then comparing it with 14-day empirical tailored…
- Trial name
- NCT03571230
- Testing
- two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline), two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone), one proton pump inhibitor(PPI)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shandong University
Colitis, Ulcerative
Antibiotics for the Treatment of Ulcerative Colitis
Ulcerative colitis (UC) is an acute and chronic inflammatory bowel disease, whose cause is unknown. However, it is widely accepted that bacteria living in the large bowel are essential for the development of the disease.
- Trial name
- NCT00355602
- Testing
- Cefuroxime, Ciprofloxacin, Clarithromycin
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Dundee
Helicobacter Pylori Infection
CANHelp Working Group Treatment Trials
The CANHelp Working Group Treatment Trials are part of a comprehensive research program carried out by the Canadian North Helicobacter pylori (CANHelp) Working Group.
- Trial name
- NCT01967329
- Testing
- Standard Triple, Sequential, Quadruple
- Where
- Canada
- Volunteers
- 338 people
- Sponsor
- University of Alberta
Mycobacterium; Xenopi, Lung Diseases
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression.
- Trial name
- AKAPI (NCT06585020)
- Testing
- Arikayce, standard treatment
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Gastric Cancer
Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer
Helicobacter pylori (H. pylori) is associated with gastric cancer in epidemiological studies.Gastric atrophy and intestinal metaplasia caused by H. pylori are considered as precancerous lesions, but whether H.
- Trial name
- NCT01002443
- Testing
- Helicobacter pylori eradication
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- National Cancer Center, Korea
Helicobacter Pylori Infection
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy.
- Trial name
- NCT04901117
- Testing
- Amoxicillin, Clarithromycin, Tetracycline
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Shandong University
Prostate Cancer
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
This clinical trial is being conducted to recommend a safe and tolerable phase 2 dose of docetaxel or cabazitaxel when combined with clarithromycin in men who have developed castrate-resistant prostate cancer.
- Trial name
- NCT03043989
- Testing
- Docetaxel, Cabazitaxel, Clarithromycin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Helicobacter Pylori Infection, Chronic Gastritis
Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.
The aim of this study is to evaluate the efficacy and safety of a quadruple therapy consisting of berberine hydrochloride, minocycline, esomeprazole, and colloidal bismuth tartrate for the first phase eradication of Helicobacter…
- Trial name
- NCT06603688
- Testing
- esomeprazole, Bismuth, Amoxicillin
- Where
- China
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital of Digestive Diseases
Helicobacter Pylori Associated Gastrointestinal Disease
Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers
To evaluate the effect of coadministration of amoxicillin and clarithromycin on safety, tolerability and pharmacokinetics of JP-1366 in healthy subjects and the effect of JP-1366 on safety, tolerability and pharmacokinetics of…
- Trial name
- NCT05194046
- Testing
- JP-1366 20mg 1capsule, Amoxicillin 500Mg Cap, Clarithromycin 500Mg Tab
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Dyspepsia
Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Peptic ulcer disease is the most common gastrointestinal disease. Antibiotic resistant Helicobacter pylori is a major problem worldwide.
- Trial name
- NCT00285688
- Testing
- gastroscopic examination
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Helicobacter Pylori Infection
S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)
The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).
- Trial name
- NCT01061437
- Testing
- PACx14, PACMx5, PAx5/PCMx5
- Where
- 7 sites in Chile, Colombia and 4 more
- Volunteers
- 1,859 people
- Sponsor
- SWOG Cancer Research Network
Healthy
Drug-Drug Interaction Study of Voriconazole With Clarithromycin.
The current study evaluated the Pharmacokinetic (PK) drug-drug interaction (PK-DDI) of voriconazole with clarithromycin in healthy male volunteers.
- Trial name
- NCT05380245
- Testing
- Voriconazole 200 mg x 2 Tablets, Clarithromycin 500 mg x 1Tablets
- Where
- Pakistan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Abdul Wali Khan University Mardan
Helicobacter Pylori Infection
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
The Asian-Pacific Consensus Report has recommended that proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori infection.
- Trial name
- NCT03383003
- Testing
- Nexium, Amolin, Klaricid
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- Chang Gung Memorial Hospital
Gastritis Associated With Helicobacter Pylori
Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication
Patients infected with H. pylori were randomly assigned to the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and…
- Trial name
- NCT02827942
- Testing
- vonoprazan 20 mg bid, Amoxicillin 500 mg tid, Amoxicillin 750 mg bid
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Hamamatsu University
Helicobacter Pylori Infection
Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era
Era of COVID-19 and the related panic lead to widely spread antibiotics misuse especially for azithromycin. Cross sensitivity between azithromycin and clarithromycin can impact success rates of H.
- Trial name
- NCT05035186
- Testing
- Amoxicillin
- Where
- Egypt
- Volunteers
- 233 people
- Sponsor
- Alexandria University
Treatment Effectiveness
Vonoprazan for Helicobacter Pylori Eradication in Adolescents
The trial tends to evaluate the efficacy of vonoprazan-based triple therapy in eradicating H. Pylori infection in adolescent patients in Egypt, in comparison to standard treatment regimens to determine if it offers superior…
- Trial name
- NCT06162949
- Testing
- Vonoprazan, Amoxicillin, Clarithromycin
- Where
- Egypt
- Volunteers
- 242 people
- Sponsor
- Alexandria University
Helicobacter Pylori Infection
10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
Helicobacter pylori (H. pylori) infection is highly associated with gastrointestinal disorders, including peptic ulcer disease, gastric cancer, and gastric mucosa associated lymphoid tissue lymphoma.1 In 1994, H.
- Trial name
- NCT02959255
- Testing
- Esomeprazole
- Where
- Greece
- Volunteers
- 364 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Mycobacterium Abscessus Lung Disease
The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance
Background: Mycobacterium abscessus, one of the most common species of nontuberculous mycobacterium (NTM), poses a significant clinical challenge due to its natural resistance to antibiotics and high treatment failure rates…
- Trial name
- NCT07514364
- Testing
- Rifabutin, No Rifabutin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a…
- Trial name
- NCT04167670
- Testing
- Vonoprazan, Amoxicillin, Clarithromycin
- Where
- 153 sites in United States, Bulgaria and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Phathom Pharmaceuticals, Inc.